Table 1.
Baseline characteristics of patients from the Danish AF cohort, GARFIELD-AF Scandinavia and GARFIELD-AF Global registries
| Danish AF cohort | GARFIELD-AF Scandinavia | GARFIELD-AF Global | |
| n | 90 693 | 2396 | 52 080 |
| Age (median (IQR)) | 75 (66.0, 83.0) | 73.0 (66.0, 78.0) | 71.0 (63.0, 78.0) |
| Sex, male (%) | 48 486 (53.5) | 1389 (58.0) | 29 068 (55.8) |
| Race, Caucasian (%) | NA | 1860 (99.3) | 32 028 (63.1) |
| Diabetes (%) | 10 900 (12.0) | 387 (16.2) | 11 555 (22.2) |
| Stroke/TIA (%) | 12 827 (14.1) | 325 (13.6) | 3879 (7.5) |
| SE (%) | 448 (0.5) | 6 (0.3) | 335 (0.6) |
| History of bleeding (%) | 10 544 (11.6) | 46 (1.9) | 1318 (2.5) |
| Vascular disease (%) | 15 305 (16.9) | 268 (11.2) | 7682 (14.8) |
| Chronic kidney disease (%) | 4224 (4.7) | 185 (7.7) | 5360 (10.3) |
| Heart failure (%) | 14 961 (16.5) | 348 (14.5) | 11 758 (22.6) |
| Ischaemic heart disease (%) | 13 445 (14.8) | 331 (13.8) | 11 265 (21.6) |
| Hypertension (%) | 55 665 (61.4) | 1659 (69.4) | 39 643 (76.3) |
| VTE or PE (%) | 5141 (5.7) | 77 (3.2) | 1355 (2.6) |
| NOAC (%) | 23 212 (25.6) | 521 (21.7) | 11 004 (21.1) |
| VKA (%) | 27 968 (30.8) | 1110 (46.3) | 20 708 (39.8) |
| OAC (%) | 51 180 (56.4) | 1631 (68.0) | 31 712 (60.8) |
| VKA + AP (%) | 10 773 (11.9) | 181 (7.6) | 4827 (9.4) |
| NOAC + AP (%) | 7608 (8.4) | 47 (2.0) | 1896 (3.7) |
| NSAID (%) | 13 078 (14.4) | 23 (1.0) | 1701 (3.3) |
| Acetylsalicylic acid (%) | 32 890 (36.3) | 413 (17.2) | 14 636 (28.1) |
| ADP-inhibitor (%) | 9128 (10.1) | 89 (3.7) | 3580 (6.9) |
| CABG (%) | 3291 (3.6) | 92 (3.9) | 1625 (3.2) |
| CHA2DS2VASC (median (IQR)) | 3.0 (2.0, 4.0) | 3.0 (2.0, 4.0) | 3.0 (2.0, 4.0) |
| CHA2DS2VASC (%) | |||
| 0 | 5678 (6.3) | 19 (0.8) | 1516 (2.9) |
| 1 | 10 231 (11.3) | 279 (11.7) | 6369 (12.4) |
| 2 | 16 137 (17.8) | 530 (22.2) | 10 230 (19.9) |
| 3 | 20 143 (22.2) | 626 (26.2) | 12 138 (23.6) |
| 4 | 19 378 (21.4) | 526 (22.1) | 11 022 (21.4) |
| 5 | 11 020 (12.2) | 238 (10.0) | 5895 (11.5) |
| >5 | 8106 (8.9) | 167 (7.0) | 4238 (8.2) |
| HAS-BLED (median (IQR)) | 2.0 (1.0, 3.0) | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) |
| HAS-BLED category n, missing (%) | 1088 (1308) | 37 549 (14 531-missing) | |
| 0 | 8297 (9.1) | 169 (15.5) | 5471 (14.6) |
| 1 | 19 956 (22.0) | 507 (46.6) | 16 169 (43.1) |
| 2 | 31 170 (34.4) | 301 (27.7) | 11 692 (31.1) |
| 3 | 24 998 (27.6) | 87 (8.0) | 3570 (9.5) |
| >3 | 6272 (6.9) | 24 (2.2) | 647 (1.7) |
| GARFIELD-AF model, stroke, median (IQR) | 1.10 (0.75, 1.82) | 0.80 (0.60, 1.10) | 0.90 (0.70, 1.40) |
| GARFIELD-AF model, bleed, median (IQR) | 1.08 (0.74, 1.54) | 0.90 (0.70,1.30) | 1.00 (0.70, 1.40) |
AP, antiplatelet therapy; CABG, coronary artery bypass grafting; GARFIELD-AF, Global Anticoagulant Registry in the FIELD-Atrial Fibrillation; NA, Not available; NOAC, non-vitamin-K antagonist; NSAID, non-steroidal anti-inflammatory drug; OAC, oral anticoagulants; PE, pulmonary embolism; SE, systemic embolism; TIA, transient ischaemic attack; VKA, vitamin-K antagonist; VTE, venous thromboembolism.